GHRP-2 — Indexed Studies

Possible Involvement of Hypothalamic Dysfunction in Long COVID Patients Characterized by Delayed Response to Gonadotropin-Releasing Hormone.

Otsuka Y, Soejima Y, Nakano Y et al.

Association between overweight and growth hormone secretion in patients with non-functioning pituitary tumors.

Seki Y, Ichihara A

ICAM1-Negative Intravascular Large B-Cell Lymphoma of the Pituitary Gland: A Case Report and Literature Review.

Naito K, Suzuki S, Ohwada C et al.

Refractory hypoglycaemia in a localised gastrointestinal stromal tumour: Case report.

Dhali A, Ray S, Dhali GK et al.

Preoperative growth hormone (GH) peak values during a GH releasing peptide-2 test reflect the severity of hypopituitarism and the postoperative recovery of GH secretion in patients with non-functioning pituitary adenomas.

Soga A, Fukuda I, Kobayashi S et al.

Idiopathic and isolated adrenocorticotropic hormone deficiency presenting as continuous epigastric discomfort without symptoms of hypoglycemia: a case report.

Okauchi S, Tatsumi F, Kan Y et al.

Secondary Adrenal Insufficiency Following Nivolumab Therapy in a Patient with Metastatic Renal Cell Carcinoma.

Seki T, Yasuda A, Oki M et al.

Laparoscopic Sleeve Gastrectomy Resolves Low GHRP-2-Stimulated Growth Hormone Levels in Obese Patients.

Ohara E, Tokuyama H, Kitamoto T et al.

Investigation of the clinical significance of the growth hormone-releasing peptide-2 test for the diagnosis of secondary adrenal failure.

Arimura H, Hashiguchi H, Yamamoto K et al.

Effects of GHRP-2 and Cysteamine Administration on Growth Performance, Somatotropic Axis Hormone and Muscle Protein Deposition in Yaks (Bos grunniens) with Growth Retardation.

Hu R, Wang Z, Peng Q et al.

One-year intranasal application of growth hormone releasing peptide-2 improves body weight and hypoglycemia in a severely emaciated anorexia nervosa patient.

Haruta I, Fuku Y, Kinoshita K et al.

Estradiol regulates GH-releasing peptide's interactions with GH-releasing hormone and somatostatin in postmenopausal women.

Norman C, Rollene NL, Erickson D et al.

Differential pulsatile secretagogue control of GH secretion in healthy men.

Norman C, Miles J, Bowers CY et al.

Urinary growth hormone level and insulin-like growth factor-1 standard deviation score (IGF-SDS) can discriminate adult patients with severe growth hormone deficiency.

Hirohata T, Saito N, Takano K et al.

The arginine and GHRP-2 tests as alternatives to the insulin tolerance test for the diagnosis of adult GH deficiency in Japanese patients: a comparison.

Kinoshita Y, Tominaga A, Usui S et al.

Regulated recovery of pulsatile growth hormone secretion from negative feedback: a preclinical investigation.

Veldhuis JD, Bowers CY

Gender, sex-steroid, and secretagogue-selective recovery from growth hormone-induced feedback in older women and men.

Veldhuis JD, Erickson D, Wigham J et al.

Complex regulation of GH autofeedback under dual-peptide drive: studies under a pharmacological GH and sex steroid clamp.

Veldhuis JD, Erickson D, Miles JM et al.

Concordant and discordant adrenocorticotropin (ACTH) responses induced by growth hormone-releasing peptide-2 (GHRP-2), corticotropin-releasing hormone (CRH) and insulin-induced hypoglycemia in patients with hypothalamopituitary disorders: evidence for direct ACTH releasing activity of GHRP-2.

Kimura T, Shimatsu A, Arimura H et al.

Secretagogue type, sex-steroid milieu, and abdominal visceral adiposity individually determine secretagogue-stimulated cortisol secretion.

Iranmanesh A, Bowers CY, Veldhuis JD

Comparison of pituitary-adrenal responsiveness between insulin tolerance test and growth hormone-releasing peptide-2 test: a pilot study.

Kano T, Sugihara H, Sudo M et al.

Pre- versus postmenopausal age, estradiol, and peptide-secretagogue type determine pulsatile growth hormone secretion in healthy women: studies using submaximal agonist drive and an estrogen clamp.

Hudson SB, Schroeder DR, Bailey JN et al.

Exaggerated response of adrenocorticotropic hormone to growth hormone-releasing peptide-2 test in Cushing's disease. Case report.

Sakihara S, Kageyama K, Matsumoto A et al.

Relative effects of estrogen, age, and visceral fat on pulsatile growth hormone secretion in healthy women.

Veldhuis JD, Hudson SB, Erickson D et al.

Preservation of GHRH and GH-releasing peptide-2 efficacy in young men with experimentally induced hypogonadism.

Veldhuis JD, Keenan DM, Bailey JN et al.

Factors other than sex steroids modulate GHRH and GHRP-2 efficacies in men: evaluation using a GnRH agonist/testosterone clamp.

Veldhuis JD, Bowers CY

Novel relationships of age, visceral adiposity, insulin-like growth factor (IGF)-I and IGF binding protein concentrations to growth hormone (GH) releasing-hormone and GH releasing-peptide efficacies in men during experimental hypogonadal clamp.

Veldhuis JD, Keenan DM, Bailey JN et al.

Determinants of GH-releasing hormone and GH-releasing peptide synergy in men.

Veldhuis JD, Bowers CY

Aromatase and 5alpha-reductase inhibition during an exogenous testosterone clamp unveils selective sex steroid modulation of somatostatin and growth hormone secretagogue actions in healthy older men.

Veldhuis JD, Mielke KL, Cosma M et al.

Secretagogues govern GH secretory-burst waveform and mass in healthy eugonadal and short-term hypogonadal men.

Veldhuis JD, Keenan DM

Gonadal status and body mass index jointly determine growth hormone (GH)-releasing hormone/GH-releasing peptide synergy in healthy men.

Paulo RC, Cosma M, Soares-Welch C et al.

Peripheral estrogen receptor-alpha selectively modulates the waveform of GH secretory bursts in healthy women.

Veldhuis JD, Keenan DM, Bowers CY

A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency.

Chihara K, Shimatsu A, Hizuka N et al.

Estimation of the size and shape of GH secretory bursts in healthy women using a physiological estradiol clamp and variable-waveform deconvolution model.

Veldhuis JD, Keenan DM, Bowers CY

Tripartite control of growth hormone secretion in women during controlled estradiol repletion.

Veldhuis JD, Cosma M, Erickson D et al.

GH response to hypoglycemia and clonidine in the GH-releasing hormone resistance syndrome.

Salvatori R, Serpa MG, Parmigiani G et al.

Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake.

Laferrère B, Hart AB, Bowers CY

Testosterone supplementation in healthy older men drives GH and IGF-I secretion without potentiating peptidyl secretagogue efficacy.

Veldhuis JD, Keenan DM, Mielke K et al.

Short-term testosterone supplementation does not activate GH and IGF-I production in postmenopausal women.

Soares-Welch C, Mielke KL, Bowers CY et al.

Joint mechanisms of impaired growth-hormone pulse renewal in aging men.

Veldhuis JD, Iranmanesh A, Bowers CY

Determinants of dual secretagogue drive of burst-like growth hormone secretion in premenopausal women studied under a selective estradiol clamp.

Erickson D, Keenan DM, Farhy L et al.

Contributions of gender and systemic estradiol and testosterone concentrations to maximal secretagogue drive of burst-like growth hormone secretion in healthy middle-aged and older adults.

Veldhuis JD, Patrie JT, Brill KT et al.

Activation of somatostatin-receptor subtype-2/-5 suppresses the mass, frequency, and irregularity of growth hormone (GH)-releasing peptide-2-stimulated GH secretion in men.

Iranmanesh A, Bowers CY, Veldhuis JD

Short-term testosterone supplementation relieves growth hormone autonegative feedback in men.

Veldhuis JD, Evans WS, Iranmanesh A et al.

Changes in appetite and body weight in response to long-term oral administration of the ghrelin agonist GHRP-2 in growth hormone deficient children.

Mericq V, Cassorla F, Bowers CY et al.

Pulsatile and nocturnal growth hormone secretions in men do not require periodic declines of somatostatin.

Dimaraki EV, Jaffe CA, Bowers CY et al.

The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone.

Van den Berghe G, Baxter RC, Weekers F et al.

Impact of estradiol supplementation on dual peptidyl drive of GH secretion in postmenopausal women.

Veldhuis JD, Evans WS, Bowers CY

E2 supplementation selectively relieves GH's autonegative feedback on GH-releasing peptide-2-stimulated GH secretion.

Anderson SM, Wideman L, Patrie JT et al.

Growth hormone-releasing peptide-2 stimulates GH secretion in GH-deficient patients with mutated GH-releasing hormone receptor.

Gondo RG, Aguiar-Oliveira MH, Hayashida CY et al.

Growth hormone (GH) secretion in patients with an inactivating defect of the GH-releasing hormone (GHRH) receptor is pulsatile: evidence for a role for non-GHRH inputs into the generation of GH pulses.

Roelfsema F, Biermasz NR, Veldman RG et al.

Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion.

Bowers CY, Granda-Ayala R

Reduction of free fatty acids by acipimox enhances the growth hormone (GH) responses to GH-releasing peptide 2 in elderly men.

Van Dam PS, Smid HE, de Vries WR et al.

Synergy of L-arginine and GHRP-2 stimulation of growth hormone in men and women: modulation by exercise.

Wideman L, Weltman JY, Patrie JT et al.

Synergy of L-arginine and growth hormone (GH)-releasing peptide-2 on GH release: influence of gender.

Wideman L, Weltman JY, Patrie JT et al.

Oral estradiol administration modulates continuous intravenous growth hormone (GH)-releasing peptide-2-driven GH secretion in postmenopausal women.

Shah N, Evans WS, Bowers CY et al.

A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness.

Van den Berghe G, Baxter RC, Weekers F et al.

Tripartite neuroendocrine activation of the human growth hormone (GH) axis in women by continuous 24-hour GH-releasing peptide infusion: pulsatile, entropic, and nyctohemeral mechanisms.

Shah N, Evans WS, Bowers CY et al.

Preservation of growth hormone secretion in response to growth hormone-releasing peptide-2 during prednisone therapy.

Meacham LR, Culler FL, Abdul-Latif H et al.

Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness.

Van den Berghe G, Wouters P, Weekers F et al.

Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans.

Arvat E, Di Vito L, Lanfranco F et al.